{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:57:58Z","timestamp":1791341878038,"version":"4.3.1"},"reference-count":41,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1080\/17474086.2024.2422554","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T10:09:37Z","timestamp":1730282977000},"page":"755-767","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS"],"prefix":"10.1080","volume":"17","author":[{"given":"Mallory","family":"Norman","sequence":"first","affiliation":[{"name":"Yale New Haven Hospital, Smilow Cancer Center, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Yamartino","sequence":"additional","affiliation":[{"name":"Yale New Haven Hospital, Smilow Cancer Center, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Gerstein","sequence":"additional","affiliation":[{"name":"Yale New Haven Hospital, Smilow Cancer Center, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-2944","authenticated-orcid":false,"given":"Rory","family":"Shallis","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Mendez","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Podoltsev","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Eighmy","sequence":"additional","affiliation":[{"name":"Yale New Haven Hospital, Smilow Cancer Center, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.005"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716984"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24072"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000570"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.2285"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112304"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.267"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00497-1"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904794"},{"key":"e_1_3_4_12_1","volume-title":"Tibsovo (ivosidenib) [Package Insert]","year":"2018","unstructured":"Tibsovo (ivosidenib) [Package Insert]. Boston (MA): Servier Pharmaceuticals LLC; 2018."},{"key":"e_1_3_4_13_1","volume-title":"Rezlidhia (olutasidenib) [Package Insert]","year":"2022","unstructured":"Rezlidhia (olutasidenib) [Package Insert]. Watertown (MA): Forma Therapeutics; 2022."},{"key":"e_1_3_4_14_1","volume-title":"Idhifa (enasidenib) [Package Insert]","year":"2017","unstructured":"Idhifa (enasidenib) [Package Insert]. Summit (NJ): Celgene Corporation; 2017."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0834"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002140"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00292-7"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009411"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187861"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779405"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0472-2"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147593"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014901"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146932"},{"key":"e_1_3_4_25_1","volume-title":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research","author":"U.S. Food and Drug Administration, FDA approves ivosidenib for myelodysplastic syndromes","unstructured":"U.S. Food and Drug Administration, FDA approves ivosidenib for myelodysplastic syndromes. U.S. Food and Drug Administration, Center for Drug Evaluation and Research; [Accessed 2024 Oct 28]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-myelodysplastic-syndromes"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30284-4"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147898"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117344"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003988"},{"key":"e_1_3_4_30_1","volume-title":"2023 ASH Annual Meeting & Exposition","author":"Smith BD","unstructured":"Smith BD, Lachoweicz CA, Ambinder AJ, et al. A comparison of acute myeloid leukemia regimens: hypomethylating agents combined with ivosidenib or venetoclax in newly diagnosed patients with IDH1 mutations: a real-world evidence study. In: 2023 ASH Annual Meeting & Exposition; San Diego, CA, USA. Abstract 971. Presented December 11, 2023."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00494-0"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_3_4_33_1","volume-title":"Presented at: 2020 ASCO Virtual Scientific Program. Abstract 7500","author":"Lachowiez CA","year":"2020","unstructured":"Lachowiez CA, Borthakur G, Loghavi S, et al. A phase Ib\/ii study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies. In: Presented at: 2020 ASCO Virtual Scientific Program. Abstract 7500; 2020."},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153660"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188341"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00604-2"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007233"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164986"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182944"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e19043"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0182"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32436-4"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00687-5"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2024.2422554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T06:14:16Z","timestamp":1731996856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2024.2422554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1080\/17474086.2024.2422554"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2024.2422554","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}